Apogee Therapeutics (APGE) Research & Development (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Research & Development data on file, last reported at $60.8 million in Q1 2026.

• On a quarterly basis, Research & Development rose 31.11% year-over-year to $60.8 million in Q1 2026; TTM through Mar 2026 was $229.1 million, a 23.5% increase from a year earlier, with the FY2025 full-year figure at $214.7 million, up 27.91% from the prior year.
• Research & Development for Q1 2026 stood at $60.8 million, up from $58.4 million in the prior quarter.
• Over the last five years, Research & Development for APGE reached as high as $60.8 million in Q1 2026 and fell as low as $1.4 million in Q2 2022.
• Historically, Research & Development has averaged $33.5 million across 5 years, with a median of $31.1 million in 2023.
• Across the five-year window, Research & Development surged 863.12% in 2023 and slipped 2.96% in 2025, its largest moves.
• Year by year, Research & Development stood at $12.2 million in 2022, then jumped by 137.17% to $29.0 million in 2023, then surged by 108.02% to $60.2 million in 2024, then declined by 2.96% to $58.4 million in 2025, then increased by 4.06% to $60.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $60.8 million in Q1 2026, $58.4 million in Q4 2025, and $54.2 million in Q3 2025.